Abstract

Colorectal cancer is the third most frequently diagnosed cancer after lung and breast cancer and, unlike these agents, has relatively few stratified molecular targets for therapy due to the complex, heterogenous nature of the disease.

In this webinar, Andrew Beggs of the University of Birmingham discusses a project that performed stratified analysis of patients as a pre-pilot for the 100,000 Genomes project. His team performed whole-genome sequencing on fresh samples and, as proof of principle, 3’ RNA-seq on matched formalin-fixed, paraffin-embedded samples.

Dr. Beggs demonstrates that by combining WGS and RNA-seq, many interesting insights can be gained into the underlying disease processes in colorectal cancer, allowing identification of new targets for therapy and disease stratification.

Dr. Lukas Paul, Senior Manager of Scientific Affairs discusses the acceleration of gene expression profiling projects with the massive multiplexing of 3’ mRNA-Seq libraries.

Speaker’s biography

Andrew-Beggs_Photo

Andrew Beggs
Professor of Cancer Genetics & Surgery, Institute of Cancer and Genomic Sciences
University of Birmingham

Andrew Beggs is a Professor of Cancer Genetics & Surgery at the University of Birmingham. He holds a Cancer Research UK Advanced Clinician Scientist Fellowship and is a fellow of the Alan Turing Institute. He carries out a broad research program in cancer including organoid models and multi-omics stratification of cancer. He has also recently branched out into pathogen diagnostics in light of the recent SARS-CoV-2 pandemic.

Lexogen_LP_Photo

Lukas Paul
Senior Manager of Scientific Affairs
Lexogen

Lukas Paul joined Lexogen GmbH as a Research Scientist and headed the RNA-Seq Service before becoming Senior Manager of Scientific Affairs. He holds a PhD in Biomolecular Sciences from the University of Manchester Institute of Technology (UK) and was a PostDoc and Staff Scientist at the Max F. Perutz Laboratories (Vienna, Austria). His academic work includes studies on RNA-protein interaction, enzymatics, RNA degradation, translation, ribosome recycling, catalytic RNA, and fluorescence assay development. In his current position at Lexogen, Lukas Paul consults on RNA-Seq projects, presents at meetings and webinars, monitors developments in the transcriptomic market, and heads collaborative projects.